Arbutus Biopharma Corporation (NASDAQ:ABUS) Getting Somewhat Negative Press Coverage, Study Shows
Press coverage about Arbutus Biopharma Corporation (NASDAQ:ABUS) has been trending somewhat negative on Tuesday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Arbutus Biopharma Corporation earned a media sentiment score of -0.12 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Arbutus Biopharma Corporation (NASDAQ:ABUS) Rating Reiterated by Chardan Capital (americanbankingnews.com)
- Arbutus Biopharma Corp’s (ABUS) CEO Mark Murray on Q2 2017 Results – Earnings Call Transcript – Seeking Alpha (seekingalpha.com)
- Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results – GlobeNewswire (press release) (globenewswire.com)
- Edited Transcript of ABUS earnings conference call or presentation 3-Aug-17 8:30pm GMT (finance.yahoo.com)
- Zacks: Analysts Expect Arbutus Biopharma Corporation (NASDAQ:ABUS) Will Announce Quarterly Sales of $680,000.00 (americanbankingnews.com)
A number of research firms have recently issued reports on ABUS. Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma Corporation in a report on Monday. Zacks Investment Research raised Arbutus Biopharma Corporation from a “sell” rating to a “hold” rating in a report on Monday, July 10th. Finally, Ladenburg Thalmann Financial Services began coverage on Arbutus Biopharma Corporation in a report on Friday, June 2nd. They issued a “buy” rating and a $32.00 target price on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $11.65.
Shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) traded up 2.82% on Tuesday, reaching $3.65. The company had a trading volume of 42,452 shares. Arbutus Biopharma Corporation has a 12 month low of $2.35 and a 12 month high of $4.10. The stock has a 50 day moving average price of $3.67 and a 200-day moving average price of $3.23. The company’s market capitalization is $200.84 million.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Stock Ratings for Arbutus Biopharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corporation and related stocks with our FREE daily email newsletter.